During the second phase of the WTCCC, samples from 30,000 individuals will be analyzed using the firm’s Genome-Wide Human SNP Array 6.0.

The Wellcome Trust of Great Britain has awarded the second phase of its Case Control Consortium (WTCCC) project to Affymetrix. This continuation of what is reportedly the largest study of the genetics behind common diseases will analyze the genetic information of 60,000 additional individuals, 30,000 of them with the Affymetrix® Genome-Wide Human SNP Array 6.0, plus 6,000 common controls.

Over the next year, 14 U.K. research groups will collaborate with the WTCCC to identify genetic contributions to 14 common diseases and drug responses, including schizophrenia, ulcerative colitis, psychosis, bacteriosis, pre-eclampsia, and statin response as well as an additional genome-wide association study study on learning difficulties. Researchers will use Affymetrix technology to genotype samples for seven of these disorders.

In the first phase of the project, Affymetrix and the Wellcome Trust collaborated to genotype more than 17,000 samples to detect 24 genetic associations across bipolar disorder, coronary artery disease, Crohn’s disease, hypertension, rheumatoid arthritis, and type 1 and 2 diabetes. More than 10 billion individual genotypes were produced as part of this project.

Previous articleGSK Commits $25M to Stem Cell Alliance with Harvard University
Next articleBlood Biomarkers for the Presence of Ruptured Atherosclerotic Plaques Identified